Here, we observed that the treatment for three weeks with a dose of 65 mg/kg BW of TriMetChalc significantly reduced hepatic steatosis in the ob/ob mice, as quantified by histological staining and PLIN2 immunohistochemistry. This evidence concerns the gene PLIN2 and fatty liver disease.